Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?
Watson is progressing on a multi-year effort to diversify beyond its core U.S. generics business into branded drugs and international markets.
You may also be interested in...
Off-Label Progesterone Use For Preventing Preterm Birth Debated At FDA Panel
Some members of FDA’s Reproductive Health Drugs Advisory Committee were not impressed that progesterone is already being used off-label to prevent preterm birth in women with a short cervix.
Columbia’s Progesterone Faces FDA Skepticism Over Foreign Data At Advisory Committee
The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.
Amgen, Watson Aim For First Joint Oncology Biosimilar In 2017 To Open International Doors
The deal is a key part of both companies’ plans for aggressive international expansion because they will be able to spread fixed costs and offer robust portfolios to vastly different geographically diverse customers.